IPP Bureau
Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management
By IPP Bureau - December 23, 2025
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Bayer wins Japan nod for finerenone in broad heart failure population
By IPP Bureau - December 23, 2025
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
China approves first-in-class TGCT drug, marking global first for pimicotinib
By IPP Bureau - December 23, 2025
FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer
By IPP Bureau - December 23, 2025
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
SRM Global Hospitals performs Tamil Nadu’s first TactiFlex radiofrequency ablation to save 80-yr-old patient
By IPP Bureau - December 23, 2025
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
LATIFY Phase III trial of Ceralasertib fails to improve survival in advanced lung cancer
By IPP Bureau - December 23, 2025
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
FDA go-ahead to Roche’s one-minute follicular lymphoma therapy
By IPP Bureau - December 23, 2025
Full approval will depend on verification of clinical benefit in a confirmatory trial
Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug
By IPP Bureau - December 23, 2025
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
By IPP Bureau - December 23, 2025
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Glenmark Pharmaceuticals USA launches Epinephrine Injection USP, multiple-dose vial
By IPP Bureau - December 23, 2025
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar
By IPP Bureau - December 23, 2025
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries
By IPP Bureau - December 23, 2025
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Cupid reduces promoter pledged stake to 20%
By IPP Bureau - December 23, 2025
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
TAKE Solutions plans AI-driven healthcare platform
By IPP Bureau - December 23, 2025
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
Zydus Partners with Bioeq for US commercialisation rights for Nufymco
By IPP Bureau - December 23, 2025
NUFYMCO BLA has been approved by the USFDA
